Bullfrog AI Holdings, Inc. Common Stock

Bullfrog AI Holdings, Inc. is a digital biopharmaceutical company focused on artificial intelligence and machine learning (AI/ML) driven analysis of medical and healthcare data in the United States. It offers bfLEAP, an AI/ML platform for analyzing preclinical and clinical data for biotechnology and pharmaceutical companies and other organizations. The company is developing BF-222, a novel formulation of mebendazole in Phase 1 for glioblastoma; BF-223, a novel prodrug of mebendazole in preclinical stage for glioblastoma; and BF-114 in discovery phase for obesity and chronic liver diseases. It has licensing agreements with George Washington University for siRNA targeting Beta2-spectrin for human diseases including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, and with Johns Hopkins University for a formulation of mebendazole for glioblastoma and human cancer or neoplastic disease. It also has a partnership with the Lieber Institute for Brain Development (LIBD) for precision treatments for CNS disorders. Founded in 2017, it is headquartered in Gaithersburg, Maryland.